Table 1. Baseline characteristics of the... | American Society of Hematology

Table 1.

Baseline characteristics of the 213 patients after allogeneic SCT who received preemptive treatment of CMV infection with either foscarnet or ganciclovir

	Foscarnet n = 110	Ganciclovir n = 103	P
Median age, years (range)	39 (12-58)	40 (14-61)	.5
Sex (male/female)	73/37	53/50	.02
Source of stem cell graft
Bone marrow	72	59	.2
Peripheral blood	38	43^*
Type of transplant
Related	77	73	.8
Unrelated	33	30
CMV serology before SCT
Recipient (pos/neg)	87/23	81/21^†	.8
Donor (pos/neg)	65/44^†	61/41^†	1.0

	Foscarnet n = 110	Ganciclovir n = 103	P
Median age, years (range)	39 (12-58)	40 (14-61)	.5
Sex (male/female)	73/37	53/50	.02
Source of stem cell graft
Bone marrow	72	59	.2
Peripheral blood	38	43^*
Type of transplant
Related	77	73	.8
Unrelated	33	30
CMV serology before SCT
Recipient (pos/neg)	87/23	81/21^†	.8
Donor (pos/neg)	65/44^†	61/41^†	1.0

SCT indicates stem cell transplantation; CMV, cytomegalovirus.

One cord blood graft.

†

One serology result each unavailable.

View Large

This Feature Is Available To Subscribers Only